cinnarizine
Trade name: Stugeron
Cinnarizine is an antihistamine and calcium channel blocker of the diphenylmethylpiperazine group. It is prescribed for nausea and vomiting due to motion sickness or other sources such as chemotherapy, vertigo, or Ménière's disease. Cinnarizine is one of the leading causes of drug-induced parkinsonism. — Wikipedia
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Earliest trial started Sep 1, 2009 (NCT01198106)
Timeline
No events for the selected filters.
Indications
Approved for
Mechanism of action
- Histamine H1 receptorANTAGONIST
HRH1 antagonist
Cinnarizine is an antihistaminic, a not competitive antagonist of the H1 receptors that, probably, also acts as sedative. Specifically, its mechanism of action seems to be double: 1) the block of the passage of Ionian Calcium from endolymph to the vestibular sensory cells, suppressing their function, 2) the vasodilatation, which ameliorates the blood flow and the metabolic availability in the vestibular nuclei, with the global result of a vestibular depression.
Voltage-gated L-type calcium channel blocker
Cinnarizine is an antihistaminic, a not competitive antagonist of the H1 receptors that, probably, also acts as sedative. Specifically, its mechanism of action seems to be double: 1) the block of the passage of Ionian Calcium from endolymph to the vestibular sensory cells, suppressing their function, 2) the vasodilatation, which ameliorates the blood flow and the metabolic availability in the vestibular nuclei, with the global result of a vestibular depression.
Chemistry & pharmacology
SMILES
C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1- Mol. weight
- 368.52 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCinnarizine ↗
- ChEMBLCHEMBL43064 ↗
Also known as
- 1-benzhydryl-4-cinnamylpiperazin
- 1-benzhydryl-4-cinnamylpiperazin
- 1-cinnamyl-4-(diphenylmethyl)piperazine
- 1-cinnamyl-4-(diphenylmethyl)piperazine
- 1-(diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine
- 1-(diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine
- 516 md
- 516 md
- cinaperazine
- cinarizina
- cinarizina
- cinarizine
- cinnarizin
- cinnarizin
- cinnarizin
- cinnarizin
- cinnarizin
- cinnarizin
- cinnarizine
- cinnarizine
- cinnarizine
- cinnarizine
- cinnarizine
- cinnarizine
- cinnarizine
- cinnarizinum
- cinnarizinum
- cinnipirine
- marzine r.f.
- mylan travel sickness
- r-1575
- r-1575
- r-516
- r-516
- stugeron
- stugeron
- stugeron fte
- stunarone
- stunarone
- stutgin
- stutgin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06321341 | Phase 4 | Jan 24, 2024 | Valenta Pharm JSC |
| NCT01939093 | Phase 4 | Mar 1, 2010 | Chulalongkorn University, National Research Council of Thailand, Thanyarak Institute |
| NCT01198106 | N/A | Sep 1, 2009 | Israel Defense Force |
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chulalongkorn University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Israel Defense Force | Government | 1 | 1 | 1 | 2009 |
| National Research Council of Thailand | Government | 1 | 0 | 1 | 2010 |
| Thanyarak Institute | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Valenta Pharm JSC | For profit | 1 | 1 | 1 | 2024 |